Mathew Ulahannan
Internal Medicine · Utica, NYNPI 1093767956
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,565 and has fallen 79.3% since, to $325 in 2023.
Across 231 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$721
- Novo Nordisk$592
- Lilly USA, LLC$412
- AbbVie$274
- Bayer$260
- AstraZeneca$243
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,773100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 40 | $721 |
| Novo Nordisk | 39 | $592 |
| Lilly USA, LLC | 24 | $412 |
| AbbVie(2 entities) | 18 | $274 |
| Bayer | 15 | $260 |
| AstraZeneca | 18 | $243 |
| Boehringer Ingelheim | 11 | $179 |
| Novartis | 11 | $175 |
| Sanofi-aventis U.S. LLC | 9 | $161 |
| Corcept Therapeutics | 7 | $119 |
| Abbott | 6 | $104 |
| Merck | 7 | $97 |
| Amgen | 4 | $83 |
| Pfizer | 5 | $74 |
| IBSA Pharma Inc. | 4 | $71 |
| Mannkind Corporation | 3 | $51 |
| Johnson & Johnson | 3 | $41 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
How this compares
$3,773 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 21 | $447 |
| Rosuvastatin Calcium | 13 | $155 |
| Losartan Potassium | 12 | $148 |
| Atorvastatin Calcium | 13 | $123 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Utica
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.